| $337M | ||
| $259M | ||
| $100M | ||
| $79M | ||
| $60M | ||
| $58M |
Buys | $29,943 | 1 | 5 |
Sells | $60,886,774 | 20 | 95 |
| Rouan Sarah Kathryn | director | 1 | $29,943 | 1 | $889,790 | $-859,847 |
| MACARTNEY LAWSON | director | 0 | $0 | 1 | $137,333 | $-137,333 |
| Mancini Marianna | Chief Operating Officer | 0 | $0 | 3 | $3.47M | $-3.47M |
| SINGLETON J MATTHEW | director | 0 | $0 | 5 | $4.58M | $-4.58M |
| ZANTE GREG | Chief Financial Officer | 0 | $0 | 4 | $13.28M | $-13.28M |
| Lian Brian | President & CEO | 0 | $0 | 6 | $38.54M | $-38.54M |
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Over the last 12 months, insiders at Viking Therapeutics, Inc. have bought $29,943 and sold $60.89M worth of Viking Therapeutics, Inc. stock.
On average, over the past 5 years, insiders at Viking Therapeutics, Inc. have bought $159,978 and sold $31.22M worth of stock each year.
Highest buying activity among insiders over the last 12 months: Rouan Sarah Kathryn (director) — $29,943.
The last purchase of 1,240 shares for transaction amount of $29,943 was made by Rouan Sarah Kathryn (director) on 2025‑03‑31.
| 2025-07-03 | Sale | Lian Brian | President & CEO | 26,889 0.0237% | $27.80 | $747,633 | +7.20% | |
| 2025-07-03 | Sale | Mancini Marianna | Chief Operating Officer | 4,266 0.0037% | $27.77 | $118,473 | +7.20% | |
| 2025-07-03 | Sale | ZANTE GREG | Chief Financial Officer | 4,266 0.0037% | $27.76 | $118,428 | +7.20% | |
| 2025-03-31 | Rouan Sarah Kathryn | director | 1,240 0.0011% | $24.15 | $29,943 | +11.90% | ||
| 2025-01-06 | Sale | Lian Brian | President & CEO | 194,490 0.1752% | $42.75 | $8.31M | -34.18% | |
| 2025-01-06 | Sale | Mancini Marianna | Chief Operating Officer | 54,215 0.0488% | $42.75 | $2.32M | -34.18% | |
| 2025-01-06 | Sale | ZANTE GREG | Chief Financial Officer | 50,309 0.0453% | $42.75 | $2.15M | -34.18% | |
| 2024-11-08 | Sale | MACARTNEY LAWSON | director | 2,000 0.0018% | $68.67 | $137,333 | -57.30% | |
| 2024-10-28 | Sale | ZANTE GREG | Chief Financial Officer | 131,687 0.1468% | $76.61 | $10.09M | -60.47% | |
| 2024-10-25 | Sale | SINGLETON J MATTHEW | director | 16,000 0.0185% | $79.50 | $1.27M | -62.23% | |
| 2024-10-25 | Sale | Rouan Sarah Kathryn | director | 11,000 0.0129% | $80.89 | $889,790 | -62.23% | |
| 2024-09-20 | Sale | Lian Brian | President & CEO | 216,130 0.1961% | $70.83 | $15.31M | -56.45% | |
| 2024-09-20 | Sale | SINGLETON J MATTHEW | director | 10,300 0.0092% | $69.50 | $715,850 | -56.45% | |
| 2024-08-21 | Sale | Lian Brian | President & CEO | 1,000 0.001% | $69.90 | $69,900 | -49.34% | |
| 2024-08-21 | Sale | SINGLETON J MATTHEW | director | 5,700 0.0055% | $69.72 | $397,430 | -49.34% | |
| 2024-08-19 | Sale | Lian Brian | President & CEO | 112,870 0.1006% | $65.80 | $7.43M | -50.25% | |
| 2024-08-19 | Sale | SINGLETON J MATTHEW | director | 16,000 0.0135% | $62.22 | $995,453 | -50.25% | |
| 2024-08-14 | Sale | SINGLETON J MATTHEW | director | 20,786 0.0186% | $57.53 | $1.2M | -42.51% | |
| 2024-07-30 | Sale | Lian Brian | President & CEO | 115,859 0.1065% | $57.58 | $6.67M | -39.50% | |
| 2024-07-30 | Sale | Mancini Marianna | Chief Operating Officer | 18,026 0.0164% | $57.13 | $1.03M | -39.50% |
| Lian Brian | President & CEO | 2388014 2.1263% | $74.72M | 0 | 17 | |
| Mancini Marianna | Chief Operating Officer | 377535 0.3362% | $11.81M | 0 | 7 | |
| ZANTE GREG | Chief Financial Officer | 168660 0.1502% | $5.28M | 0 | 11 | |
| MACARTNEY LAWSON | director | 47965 0.0427% | $1.5M | 1 | 4 | +92.12% |
| SINGLETON J MATTHEW | director | 9500 0.0085% | $297,255.00 | 1 | 5 | <0.0001% |
| Rouan Sarah Kathryn | director | 1240 0.0011% | $38,799.60 | 1 | 3 | |
| LIGAND PHARMACEUTICALS INC | 10 percent owner | 5819383 5.1815% | $182.09M | 0 | 3 | |
| FOEHR MATTHEW W | 111250 0.0991% | $3.48M | 5 | 1 | +1.62% | |
| MORNEAU MICHAEL | VP, Finance and Administration | 94035 0.0837% | $2.94M | 0 | 1 | |
| Rowland Charles A Jr | director | 30000 0.0267% | $938,700.00 | 1 | 1 | +92.12% |
| Webster Stephen W | director | 8000 0.0071% | $250,320.00 | 1 | 0 | +92.12% |
$11,588,217 | 69 | 42.07% | $2.67B | |
$224,368,761 | 42 | 28.26% | $2.63B | |
$140,165,669 | 33 | 85.24% | $2.99B | |
$1,275,975,557 | 32 | 19.44% | $3.69B | |
$62,927,079 | 29 | 14.02% | $4.05B | |
$1,801,511 | 23 | 18.58% | $2.6B | |
$128,181,928 | 16 | 18.84% | $4.1B | |
$57,686,748 | 13 | 21.11% | $3.92B | |
$177,517,505 | 13 | 16.65% | $4.15B | |
$70,151,579 | 12 | 22.57% | $3.62B | |
$75,296,816 | 12 | 37.23% | $3.17B | |
$91,269,919 | 12 | 12.86% | $3B | |
$35,908,794 | 10 | 126.31% | $3.27B | |
$117,959,652 | 9 | -12.47% | $3.1B | |
Viking Therapeutics, Inc. (VKTX) | $1,711,150 | 9 | 31.59% | $3.51B |
$4,623,072 | 7 | 11.07% | $2.93B | |
$182,500,000 | 6 | 29.00% | $3.79B | |
$602,180 | 4 | -26.17% | $3.76B | |
$36,900,000 | 3 | -9.12% | $3.79B |
| Increased Positions | 234 | +51.54% | 12M | +15.23% |
| Decreased Positions | 203 | -44.71% | 15M | -18.94% |
| New Positions | 68 | New | 2M | New |
| Sold Out Positions | 104 | Sold Out | 4M | Sold Out |
| Total Postitions | 485 | +6.83% | 79M | -3.72% |
| Fmr Llc | $490,765.00 | 14.92% | 16.72M | +96,008 | +0.58% | 2024-12-31 |
| Vanguard Group Inc | $298,663.00 | 9.08% | 10.17M | +4,827 | +0.05% | 2024-12-31 |
| Blackrock, Inc. | $175,469.00 | 5.34% | 5.98M | +103,490 | +1.76% | 2025-03-31 |
| State Street Corp | $144,612.00 | 4.4% | 4.93M | +251,423 | +5.38% | 2024-12-31 |
| Morgan Stanley | $76,149.00 | 2.32% | 2.59M | +718,770 | +38.34% | 2024-12-31 |
| Jpmorgan Chase & Co | $63,345.00 | 1.93% | 2.16M | +41,105 | +1.94% | 2024-12-31 |
| Pictet Asset Management Holding Sa | $56,413.00 | 1.72% | 1.92M | +684,343 | +55.32% | 2025-03-31 |
| Geode Capital Management, Llc | $55,218.00 | 1.68% | 1.88M | +17,046 | +0.92% | 2024-12-31 |
| Citadel Advisors Llc | $43,602.00 | 1.33% | 1.49M | +12,403 | +0.84% | 2024-12-31 |
| Braidwell Lp | $43,443.00 | 1.32% | 1.48M | +322,689 | +27.89% | 2024-12-31 |